Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Health Sciences profile

Dr Ruth Savage

PositionSenior Lecturer
DepartmentDepartment of Primary Care and Clinical Simulation (Christchurch)
QualificationsMB BS MSc
Research summaryMedical Assessor for the New Zealand Pharmacovigilance Centre

Research

Ruth undertakes research in adverse drug reaction monitoring (pharmacovigilance) and rational prescribing and has experience in pharmacoepidemiology studies.

Ruth is also Senior Medical Assessor in the Centre for Adverse Reactions Monitoring (CARM), New Zealand Pharmacovigilance Centre, Dept of Preventive and Social Medicine, University of Otago, Dunedin where a high proportion of the suspected adverse reaction reports submitted by health professionals are from primary care. She is also an expert advisor to the New Zealand Medicines Adverse Reactions Committee. As a consultant to the Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden Ruth also undertakes research and provides training in international pharmacovigilance.

Publications

Rudolph, A., & Savage, R. (2023). Vulval aphthous ulcers in adolescents following COVID-19 vaccination: Analysis of an international case series. Journal of Pediatric & Adolescent Gynecology. Advance online publication. doi: 10.1016/j.jpag.2023.03.006

Savage, R. L. (2022). The value of complementary approaches to causality assessment for individual case safety reports: The example of Artemisia annua and hepatotoxicity. In J. Barnes (Ed.), Pharmacovigilance for herbal and traditional medicines. (pp. 211-220). Cham, Switzerland: Springer. doi: 10.1007/978-3-031-07275-8

Wilson, G., Windner, Z., Bidwell, S., Dowell, A., Toop, L., Savage, R., & Hudson, B. (2021). Navigating the health system during COVID-19: Primary care perspectives on delayed patient care. New Zealand Medical Journal, 134(1546), 17-27. Retrieved from https://www.nzma.org.nz/journal

Wilson, G., Windner, Z., Bidwell, S., Currie, O., Dowell, A., Halim, A. A., Toop, L., Savage, R., Ranaweera, U., Beadel, H., & Hudson, B. (2021). 'Here to stay': Changes to prescribing medication in general practice during the COVID-19 pandemic in New Zealand. Journal of Primary Health Care, 13(3), 222-230. doi: 10.1071/hc21035

Rocca, E., Gauffin, O., Savage, R., Vidlin, S. H., & Grundmark, B. (2021). Remdesivir in the COVID-19 pandemic: An analysis of spontaneous reports in VigiBase during 2020. Drug Safety, 44, 987-998. doi: 10.1007/s40264-021-01091-x

Savage, R. L. (2022). The value of complementary approaches to causality assessment for individual case safety reports: The example of Artemisia annua and hepatotoxicity. In J. Barnes (Ed.), Pharmacovigilance for herbal and traditional medicines. (pp. 211-220). Cham, Switzerland: Springer. doi: 10.1007/978-3-031-07275-8

Chapter in Book - Research

Rudolph, A., & Savage, R. (2023). Vulval aphthous ulcers in adolescents following COVID-19 vaccination: Analysis of an international case series. Journal of Pediatric & Adolescent Gynecology. Advance online publication. doi: 10.1016/j.jpag.2023.03.006

Journal - Research Article

Rocca, E., Gauffin, O., Savage, R., Vidlin, S. H., & Grundmark, B. (2021). Remdesivir in the COVID-19 pandemic: An analysis of spontaneous reports in VigiBase during 2020. Drug Safety, 44, 987-998. doi: 10.1007/s40264-021-01091-x

Journal - Research Article

Russom, M., Fitsum, Y., Abraham, A., & Savage, R. L. (2021). Diclofenac and the risk of rhabdomyolysis: Analysis of publications and the WHO Global Pharmacovigilance Database. Drugs: Real World Outcomes, 8, 263-275. doi: 10.1007/s40801-021-00240-z

Journal - Research Article

Wilson, G., Currie, O., Bidwell, S., Saeed, B., Dowell, A., Halim, A. A., Toop, L., Richardson, A., Savage, R., & Hudson, B. (2021). Empty waiting rooms: The New Zealand general practice experience with telehealth during the COVID-19 pandemic. New Zealand Medical Journal, 134(1538), 89-101. Retrieved from https://www.nzma.org.nz/journal

Journal - Research Article

Wilson, G., Windner, Z., Bidwell, S., Currie, O., Dowell, A., Halim, A. A., Toop, L., Savage, R., Ranaweera, U., Beadel, H., & Hudson, B. (2021). 'Here to stay': Changes to prescribing medication in general practice during the COVID-19 pandemic in New Zealand. Journal of Primary Health Care, 13(3), 222-230. doi: 10.1071/hc21035

Journal - Research Article

Wilson, G., Windner, Z., Bidwell, S., Dowell, A., Toop, L., Savage, R., & Hudson, B. (2021). Navigating the health system during COVID-19: Primary care perspectives on delayed patient care. New Zealand Medical Journal, 134(1546), 17-27. Retrieved from https://www.nzma.org.nz/journal

Journal - Research Article

Hegerius, A., Caduff-Janosa, P., Savage, R., & Ellenius, J. (2020). E-learning in pharmacovigilance: An evaluation of microlearning-based modules developed by Uppsala Monitoring Centre. Drug Safety, 43, 1171-1180. doi: 10.1007/s40264-020-00981-w

Journal - Research Article

Kuan, I. H. S., Savage, R. L., Duffull, S. B., Walker, R. J., & Wright, D. F. B. (2019). The association between metformin therapy and lactic acidosis. Drug Safety, 42, 1449-1469. doi: 10.1007/s40264-019-00854-x

Journal - Research Article

Maggo, S. D. S., Savage, R. L., & Kennedy, M. A. (2016). Impact of new genomic technologies on understanding adverse drug reactions. Clinical Pharmacokinetics, 55(4), 419-436. doi: 10.1007/s40262-015-0324-9

Journal - Research Article

Savage, R. L., Zekarias, A., & Caduff-Janosa, P. (2015). Varenicline and abnormal sleep related events. Sleep, 38(5), 833-837. doi: 10.5665/sleep.4686

Journal - Research Article

Harrison-Woolrych, M., Maggo, S., Tan, M., Savage, R., & Ashton, J. (2012). Cardiovascular events in patients taking varenicline: A case series from intensive postmarketing surveillance in New Zealand. Drug Safety, 35(1), 33-43. doi: 10.2165/11597690-000000000-00000

Journal - Research Article

Savage, R. L., Star, K., & Hill, R. (2012). Severe muscle symptoms with lipid-lowering agents may be confused with neurogenic claudication associated with spinal canal stenosis. International Journal of Risk & Safety in Medicine, 24(4), 215-219. doi: 10.3233/jrs-2012-0577

Journal - Research Article

Savage, R. L., Kunac, D. L., & Johansson, J. (2009). Appraising the post-marketing safety of medicines: A description of national and international pharmacovigilance with a focus on medicines used in chronic pain. Current Anaesthesia & Critical Care, 20(5-6), 215-220. doi: 10.1016/j.cacc.2009.07.013

Journal - Research Article

Gwynne Jones, D. P., Savage, R. L., & Highton, J. (2008). Alendronate-induced synovitis. Journal of Rheumatology, 35(3), 537-538.

Journal - Research Article

Jenks, K. A., Stamp, L. K., O'Donnell, J. L., Savage, R. L., & Chapman, P. T. (2007). Leflunomide-associated infections in rheumatoid arthritis. Journal of Rheumatology, 34, 2201-2203.

Journal - Research Article

Tatley, M., & Savage, R. (2007). Psychiatric adverse reactions with statins, fibrates and ezetimibe: Implications for the use of lipid-lowering agents. Drug Safety, 30(3), 195-201.

Journal - Research Article

Savage, R. L., Highton, J., Boyd, I. W., & Chapman, P. (2006). Pneumonitis associated with leflunomide: A profile of New Zealand and Australian reports. Internal Medicine Journal, 36, 162-169.

Journal - Research Article

Gwynne Jones, D., Savage, R., & Highton, J. (2005). Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome. BMJ, 330, 7482, 74. doi: 10.1136/bmj.330.7482.74

Journal - Research Article

Savage, R. (2005). Cyclo-oxygenase-2 inhibitors: When should they be used in the elderly? Drugs & Aging, 22(3), 185-200.

Journal - Research Article

Savage, R. (2005). Thiazolidinediones and lowered high density lipoprotein cholesterol. WHO Signal, February, 6-8.

Journal - Research Article

Coulter, D. M., Clark, D. W., & Savage, R. (2003). Celecoxib, rofecoxib, and acute temporary visual impairment. British Medical Journal, 327, 1214-1215.

Journal - Research Article

Savage, R. (2002). Loratadine. WHO Pharmaceuticals Newsletter, (2), 12.

Journal - Research Article

Savage, R. (2002). Proton pump inhibitors. WHO Pharmaceuticals Newsletter, (2), 12.

Journal - Research Article

Savage, R., & Coulter, D. M. (2000). Oral contraceptives and venous thromboembolism [Letter]. New Ethicals Journal, 24.

Journal - Research Article

The ADR Signals Analysis Project (ASAP) Team, including Savage, R. (1997). How does cystitis affect a comparative risk profile of tiaprofenic acid with other nonsteroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. Pharmacology & Toxicology, 80(5), 211-217. doi: 10.1111/j.1600-0773.1997.tb01962.x

Journal - Research Article

Bennett, M., Chang, C. L., Tatley, M., Savage, R., & Hancox, R. J. (2021). The safety of cardio-selective beta1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Research, 7, 1-10. doi: 10.1183/23120541.00801-2020

Journal - Research Other

Savage, R. L., Hill, G. R., Barnes, J., Kenyon, S. H., & Tatley, M. V. (2019). Suspected hepatotoxicity with a supercritical carbon dioxide extract of Artemisia annua in grapeseed oil used in New Zealand [Brief research report article]. Frontiers in Pharmacology, 10, 1448. doi: 10.3389/fphar.2019.01448

Journal - Research Other

Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y

Journal - Research Other

Savage, R. L., Castellano, M., & Tatley, M. V. (2017). International reports of unexpected low plasma concentrations of dabigatran suggest that more frequent measurements will add value. Seminars in Thrombosis & Hemostasis, 43(6), 635-638. doi: 10.1055/s-0037-1603361

Journal - Research Other

Castellano, M., Sartori, D., & Savage, R. (2016). Dabigatran and thromboembolism: Analysis of case histories for risk factors. WHO Pharmaceuticals Newsletter, 3, 15-22. Retrieved from http://www.who.int/medicines/publications/newsletter/en/

Journal - Research Other

Savage, R. (2016). Vemurafenib and atrial fibrillation: Signal strengthening. WHO Pharmaceuticals Newsletter, 1, 17-22. Retrieved from http://www.who.int/medicines/publications/newsletter/en/

Journal - Research Other

Savage, R. (2015). Brentuximab and hepatic disorders. WHO Pharmaceuticals Newsletter, 2, 17-22. Retrieved from http://www.who.int/medicines/publications/PharmaNewsletter2_15/en/

Journal - Research Other

Wells, J. E., Cross, N. B., Savage, R. L., Parkin, L., Horsburgh, S., & Richardson, A. K. (2015). Renal replacement therapy associated with lithium nephrotoxicity in New Zealand. New Zealand Medical Journal, 128(1425). Retrieved from http://www.nzma.org.nz/journal

Journal - Research Other

Savage, R. (2014). Tocilizumab: Psoriasis and aggravated psoriasis. WHO Pharmaceuticals Newsletter, 2, 16-21. Retrieved from http://www.who.int/medicines/publications/PharmNewsletter2_14/en/

Journal - Research Other

Savage, R. (2013). Donepezil: Syncope, heart block and beta-adrenergic blockade. Prescriber Update, 34(3), 30. Retrieved from http://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2013). The New Zealand Centre for Adverse Reactions Monitoring: A source of practice-based evidence. Journal of Primary Health Care, 5(2), 170-173. doi: 10.1071/HC13170

Journal - Research Other

Savage, R. (2012). Dronedarone, hyperthyroidism and decreased thyroid stimulating hormone. WHO Pharmaceuticals Newsletter, 4, 14-18. Retrieved from http://www.who.int/medicines/publications/PharmNewsletter4_12/en/

Journal - Research Other

Savage, R. (2012). Venlafaxine, pre-eclampsia, eclampsia and related disorders of pregnancy. WHO Pharmaceuticals Newsletter, 1, 19-22. Retrieved from http://www.who.int/medicines/publications/PharmNewsletter1_12/en/

Journal - Research Other

Savage, R. L. (2010). Leflunomide in combination therapy for rheumatoid arthritis [Editorial]. Drug Safety, 33(6), 523-526. doi: 10.2165/11532390-000000000-00000

Journal - Research Other

Meyboom, R. H. B., Star, K., Bate, J., Savage, R., & Edwards, I. R. (2008). TNF-α inhibitors and leukaemia: International pharmacovigilance reports [Letter to the editor]. Drug Safety, 31(5), 445-447. doi: 10.2165/00002018-200831050-00013

Journal - Research Other

Savage, R. (2008). Leflunomide: Update on serious toxicity. Prescriber Update, 29(1), 13-14. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2008). Tumour necrosis factor inhibitors: Recognise and treat infection promptly. Prescriber Update, 29(1), 5-6. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2007). Glitazones: Fluid retention, cardiac failure and macular oedema. Prescriber Update, 28(1), 8-10. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2007). Serious reactions with tramadol: Seizures and serotonin syndrome. Prescriber Update, 28(1), 11-13. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2006). Alendronate and inflammatory adverse reactions. Prescriber Update, 27(1), 4-6. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2006). Evidence for tramadol-warfarin interaction. Prescriber Update, 27(2), 23-24. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2006). Leflunomide and pneumonitis. Prescriber Update, 27(1), 7-8. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Ng, J., Savage, R., & McQueen, F. (2005). Churg-Strauss vasculitis syndrome and leukotriene receptor antagonists [Research Letter]. Annals of the Rheumatic Diseases, 64, 1382.

Journal - Research Other

Savage, R. L., & Kiuru, A. (2005). Thiazolidinediones and lowered HDL cholesterol [Research Letter]. Diabetes Care, 28(9), 2329-2330.

Journal - Research Other

Savage, R., & Rademaker, M. (2005). Topical corticosteroids: Face facts. Prescriber Update, 26(2), 30-31. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R., & Tatley, M. (2004). Myopathy with statins: Check CK levels and interactions. Prescriber Update, 25(1), 4-5. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2002). A dangerous trio. Prescriber Update, 23(2), 20. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2002). Can patients stomach COX-2 inhibitors? Prescriber Update, 23(2), 18-19. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2002). Venous thromoembolism with Diane 35TM and Estelle 35TM. Prescriber Update, 23(1), 2-3. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2001). NSAIAs can cause lower GIT damage. Prescriber Update, 21, 25-27. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2001). Tiaprofenic acid-induced cystitis. Prescriber Update, 22, 18-21. Retrieved from https://www.medsafe.govt.nz/publications/prescriber-update.asp

Journal - Research Other

Savage, R. (2000). Omeprazole-induced interstitial nephritis. Prescriber Update, 20, 11-13. Retrieved from https://www.moh.govt.nz

Journal - Research Other

Savage, R. (1997). Current debate: Oral contraceptives and venous thromboembolism. PreMec Bulletin, November.

Journal - Research Other

Savage, R. (1997). Oral contraceptives and venous thromboembolism [Letter]. New Zealand Medical Journal, 107, 109.

Journal - Research Other

More publications...